441 related articles for article (PubMed ID: 20664173)
21. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
Boon MR; Kooijman S; van Dam AD; Pelgrom LR; Berbée JF; Visseren CA; van Aggele RC; van den Hoek AM; Sips HC; Lombès M; Havekes LM; Tamsma JT; Guigas B; Meijer OC; Jukema JW; Rensen PC
FASEB J; 2014 Dec; 28(12):5361-75. PubMed ID: 25154875
[TBL] [Abstract][Full Text] [Related]
22. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
[TBL] [Abstract][Full Text] [Related]
23. Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.
Tam J; Szanda G; Drori A; Liu Z; Cinar R; Kashiwaya Y; Reitman ML; Kunos G
Mol Metab; 2017 Oct; 6(10):1113-1125. PubMed ID: 29031713
[TBL] [Abstract][Full Text] [Related]
24. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
26. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
28. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Martín-García E; Burokas A; Martín M; Berrendero F; Rubí B; Kiesselbach C; Heyne A; Gispert JD; Millán O; Maldonado R
J Neurochem; 2010 Mar; 112(5):1338-13351. PubMed ID: 20028452
[TBL] [Abstract][Full Text] [Related]
29. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
[TBL] [Abstract][Full Text] [Related]
31. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
Mukhopadhyay P; Bátkai S; Rajesh M; Czifra N; Harvey-White J; Haskó G; Zsengeller Z; Gerard NP; Liaudet L; Kunos G; Pacher P
J Am Coll Cardiol; 2007 Aug; 50(6):528-36. PubMed ID: 17678736
[TBL] [Abstract][Full Text] [Related]
33. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Jourdan T; Djaouti L; Demizieux L; Gresti J; Vergès B; Degrace P
Diabetes; 2010 Apr; 59(4):926-34. PubMed ID: 20110567
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
35. Beneficial metabolic effects of CB1R anti-sense oligonucleotide treatment in diet-induced obese AKR/J mice.
Tang Y; Ho G; Li Y; Hall MA; Hills RL; Black SC; Liang Y; Demarest KT
PLoS One; 2012; 7(8):e42134. PubMed ID: 22870290
[TBL] [Abstract][Full Text] [Related]
36. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Gelfand EV; Cannon CP
Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766
[TBL] [Abstract][Full Text] [Related]
37. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Bronander KA; Bloch MJ
Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
[TBL] [Abstract][Full Text] [Related]
38. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
Cooper ME; Regnell SE
Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
[TBL] [Abstract][Full Text] [Related]
39. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
40. Peripherally restricted CB1 receptor blockers.
Chorvat RJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4751-60. PubMed ID: 23902803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]